BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
8/24/2021 2:07:00 AM | Browse: 481 | Download: 819
 |
Received |
|
2021-01-04 17:53 |
|
Peer-Review Started |
|
2021-01-04 17:54 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2021-04-25 18:01 |
|
Revised |
|
2021-04-27 14:58 |
|
Second Decision |
|
2021-07-06 10:04 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Executive Editor-in-Chief |
|
2021-07-06 10:31 |
|
Articles in Press |
|
2021-07-06 10:31 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
2021-07-19 02:01 |
|
Typeset the Manuscript |
|
2021-08-16 03:41 |
|
Publish the Manuscript Online |
|
2021-08-24 02:07 |
| ISSN |
2307-8960 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Oncology |
| Manuscript Type |
Case Report |
| Article Title |
S-1 plus temozolomide as second-line treatment for neuroendocrine carcinoma of the breast: A case report
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Xin Wang, Yan-Fen Shi, Jiang-Hui Duan, Chao Wang and Huang-Ying Tan |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Huang-Ying Tan, MD, PhD, Chief Physician, Department of Integrative Oncology, China-Japan Friendship Hospital, No. 2 Yinghuadong Street, Beijing 100029, China. tanhuangying@263.net |
| Key Words |
Neuroendocrine carcinoma; Breast; S-1; Temozolomide; Case report |
| Core Tip |
Neuroendocrine carcinoma of the breast (NECB) are highly malignant tumours. There is no standard treatment protocol for NECB due to its rarity. we treated this patient with the S-1 combined with temozolomide (STEM) regimen as second-line treatment due to disease progression. The effect of the STEM regimen on the patient was good, and she achieved a progression-free survival of 23 mo. During the chemotherapy period, the patient achieved a partial response and suffered only grade-1 adverse reactions. This report can serve as a reference for clinical practice. |
| Publish Date |
2021-08-24 02:07 |
| Citation |
Wang X, Shi YF, Duan JH, Wang C, Tan HY. S-1 plus temozolomide as second-line treatment for neuroendocrine carcinoma of the breast: A case report. World J Clin Cases 2021; 9(24): 7146-7153 |
| URL |
https://www.wjgnet.com/2307-8960/full/v9/i24/7146.htm |
| DOI |
https://dx.doi.org/10.12998/wjcc.v9.i24.7146 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
